{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:28:45Z","timestamp":1792121325084,"version":"4.4.0"},"reference-count":626,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:p>Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism through the normalization of hyperprolactinemia and control of tumor mass. Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy. Recent data indicating successful withdrawal of these agents in a subset of patients challenge the previously held concept that medical therapy is a lifelong requirement. Complicated situations, such as those encountered in resistance to dopamine agonists, pregnancy, and giant or malignant prolactinomas, may require multimodal therapy involving surgery, radiotherapy, or both. Progress in elucidating the mechanisms underlying the pathogenesis of prolactinomas may enable future development of novel molecular therapies for treatment-resistant cases. This review provides a critical analysis of the efficacy and safety of the various modes of therapy available for the treatment of patients with prolactinomas with an emphasis on challenging situations, a discussion of the data regarding withdrawal of medical therapy, and a foreshadowing of novel approaches to therapy that may become available in the future.<\/jats:p>","DOI":"10.1210\/er.2005-9998","type":"journal-article","created":{"date-parts":[[2006,8,7]],"date-time":"2006-08-07T14:23:39Z","timestamp":1154960619000},"page":"485-534","source":"Crossref","is-referenced-by-count":663,"title":["Advances in the Treatment of Prolactinomas"],"prefix":"10.1210","volume":"27","author":[{"given":"Mary P.","family":"Gillam","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Molecular Medicine (M.P.G., M.E.M.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Molecular Medicine (M.P.G., M.E.M.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (G.L., A.C.), University \u201cFederico II\u201d of Naples, Naples 80131, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (G.L., A.C.), University \u201cFederico II\u201d of Naples, Naples 80131, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2006,5,26]]},"reference":[{"key":"2020071611563648000_R1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3181\/00379727-29-6288","article-title":"A new hormone of the anterior pituitary.","volume":"29","author":"Riddle","year":"1932","journal-title":"Proc Soc Exptl Biol Med"},{"key":"2020071611563648000_R2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1152\/ajplegacy.1933.105.1.191","article-title":"The preparation, identification and assay of prolactin\u2014a hormone of the anterior pituitary.","volume":"105","author":"Riddle","year":"1933","journal-title":"Am J Physiol"},{"key":"2020071611563648000_R3","first-page":"614","article-title":"Studies on the physiology of reproduction in birds.","volume":"97","author":"Riddle","year":"1931","journal-title":"Am J Physiol"},{"key":"2020071611563648000_R4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(61)90359-2","article-title":"Lactogenic activity of human pituitary growth hormone.","volume":"2","author":"Chardwick","year":"1961","journal-title":"Lancet"},{"key":"2020071611563648000_R5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/190632a0","article-title":"Prolactin activity of human growth hormone.","volume":"190","author":"Ferguson","year":"1961","journal-title":"Nature"},{"key":"2020071611563648000_R6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1210\/jcem-14-3-265","article-title":"A syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation.","volume":"14","author":"Forbes","year":"1954","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/jcem-28-8-1183","article-title":"Lactation in the absence of human growth hormone.","volume":"28","author":"Rimoin","year":"1968","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.170.3959.745","article-title":"Prolactin: evidence that it is separate from growth hormone in human blood.","volume":"170","author":"Frantz","year":"1970","journal-title":"Science"},{"key":"2020071611563648000_R9","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.68.8.1902","article-title":"A radioimmunoassay for human prolactin.","volume":"68","author":"Hwang","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611563648000_R10","first-page":"64","article-title":"Amenorre\u0301a y galactorre\u0301a.","volume":"11","author":"Ahumada","year":"1932","journal-title":"Bol Soc Obst Y Ginec"},{"key":"2020071611563648000_R11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(01)19300-1","article-title":"Spontaneous lactation associated with enlargement of the pituitary.","volume":"1","author":"Krestin","year":"1932","journal-title":"Lancet"},{"key":"2020071611563648000_R12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0002-9378(16)39969-0","article-title":"Chiari-Frommel syndrome.","volume":"51","author":"Mendel","year":"1946","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/jcem-13-1-79","article-title":"A syndrome characterized by estrogenic insufficiency, galactorrhea and decreased urinary gonadotropin.","volume":"13","author":"Argonz","year":"1953","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jcem-34-1-192","article-title":"Prolactin synthesis and secretion in a patient with the Forbes Albright syndrome.","volume":"34","author":"Friesen","year":"1972","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","article-title":"Growth hormone and prolactin excess.","volume":"352","author":"Colao","year":"1998","journal-title":"Lancet"},{"key":"2020071611563648000_R16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas.","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"key":"2020071611563648000_R17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","article-title":"Age-related and gender-related occurrence of pituitary adenomas.","volume":"41","author":"Mindermann","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R19","article-title":"Pituitary tumors in childhood.","author":"Colao","year":"2004"},{"key":"2020071611563648000_R20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3171\/jns.1994.80.2.0209","article-title":"Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery.","volume":"80","author":"Partington","year":"1994","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R21","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01137.x","article-title":"Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.","volume":"53","author":"George","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.7326\/0003-4819-100-1-115","article-title":"Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases.","volume":"100","author":"Koppelman","year":"1984","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0002-9378(81)90553-6","article-title":"Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas.","volume":"139","author":"March","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis.","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","article-title":"The natural history of untreated microprolactinomas.","volume":"48","author":"Sisam","year":"1987","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R27","first-page":"175","article-title":"Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment.","volume":"584","author":"Von Werder","year":"1982","journal-title":"Excerpta Med Int Congr Ser"},{"key":"2020071611563648000_R28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1227\/00006123-198302000-00008","article-title":"Natural history of microprolactinomas: six-year follow-up.","volume":"12","author":"Weiss","year":"1983","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0029-1211978","article-title":"Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.","volume":"106","author":"Hofle","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2020071611563648000_R30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9343(86)90020-3","article-title":"Lack of demonstrable tumor growth in progressive hyperprolactinemia.","volume":"80","author":"Sisam","year":"1986","journal-title":"Am J Med"},{"key":"2020071611563648000_R31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","article-title":"Medical treatment of prolactinomas.","volume":"28","author":"Molitch","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071611563648000_R32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09513599209015553","article-title":"The effect of combined estrogen\/progestogen treatment in women with hyperprolactinemic amenorrhea.","volume":"6","author":"Fahy","year":"1992","journal-title":"Gynecol Endocrinol"},{"key":"2020071611563648000_R34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03349744","article-title":"Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.","volume":"18","author":"Garcia","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R35","first-page":"562","article-title":"Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study.","volume":"118","author":"Kovacs","year":"1994","journal-title":"Arch Pathol Lab Med"},{"key":"2020071611563648000_R36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.1999.00754.x","article-title":"Classical pituitary apoplexy: clinical features, management and outcome.","volume":"51","author":"Randeva","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11102-005-1050-3","article-title":"Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases.","volume":"7","author":"Sibal","year":"2005","journal-title":"Pituitary"},{"key":"2020071611563648000_R38","first-page":"2190","article-title":"Conservative management of pituitary apoplexy: a prospective study.","volume":"80","author":"Maccagnan","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1227\/00006123-199006000-00010","article-title":"Clinical versus subclinical pituitary apoplexy: presentation, surgical management, and outcome in 21 patients.","volume":"26","author":"Onesti","year":"1990","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.med.0000140007.57133.4b","article-title":"Surgical techniques in transsphenoidal surgery: what is the standard of care in pituitary adenoma surgery?","volume":"14","author":"Jane","year":"2004","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"2020071611563648000_R41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0889-8529(05)70059-1","article-title":"Pituitary surgery.","volume":"28","author":"Laws Jr","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071611563648000_R42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1227\/01.NEU.0000134287.19377.A2","article-title":"Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases.","volume":"55","author":"Couldwell","year":"2004","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R43","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/foc.2004.16.4.3","article-title":"Contemporary management of prolactinomas","volume":"16","author":"Liu","year":"2004","journal-title":"Neurosurg Focus"},{"key":"2020071611563648000_R44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1009991631761","article-title":"Endoscopic pituitary surgery.","volume":"2","author":"Jho","year":"1999","journal-title":"Pituitary"},{"key":"2020071611563648000_R45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1227\/01.NEU.0000137330.02549.0D","article-title":"Endoscopic endonasal transsphenoidal surgery.","volume":"55","author":"Cappabianca","year":"2004","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/02688690050175229","article-title":"Endoscopic transsphenoidal pituitary surgery: various surgical techniques and recommended steps for procedural transition.","volume":"14","author":"Jho","year":"2000","journal-title":"Br J Neurosurg"},{"key":"2020071611563648000_R47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3171\/jns.2002.97.2.0293","article-title":"Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas.","volume":"97","author":"Cappabianca","year":"2002","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4065\/74.7.661","article-title":"Preliminary comparison of the endoscopic transnasal vs. the sublabial transseptal approach for clinically nonfunctioning pituitary macroadenomas.","volume":"74","author":"Sheehan","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/01.mlg.0000147925.04605.cc","article-title":"Safety of minimally invasive pituitary surgery (MIPS) compared with a traditional approach.","volume":"114","author":"White","year":"2004","journal-title":"Laryngoscope"},{"issue":"Suppl 1","key":"2020071611563648000_R50","doi-asserted-by":"crossref","first-page":"158s","DOI":"10.1016\/S0753-3322(02)00228-7","article-title":"Endoscopic approach to the pituitary lesions: contemporary method and review of the literature","volume":"56","author":"Kuroki","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"2020071611563648000_R51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3171\/jns.2003.98.2.0350","article-title":"Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions.","volume":"98","author":"Zada","year":"2003","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0090-3019(02)00892-3","article-title":"Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas.","volume":"58","author":"Cho","year":"2002","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1179\/016164102101199882","article-title":"Minimally invasive endoscope-assisted endonasal trans-sphenoidal microsurgery for pituitary tumors: experience with 215 cases comparing with sublabial trans-sphenoidal approach.","volume":"24","author":"Kawamata","year":"2002","journal-title":"Neurol Res"},{"key":"2020071611563648000_R54","first-page":"405","article-title":"The pituitary.","author":"Fahlbusch","year":"2002"},{"key":"2020071611563648000_R55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00701-004-0229-0","article-title":"Intra-operative magnetic resonance imaging in neurosurgery.","volume":"146","author":"Albayrak","year":"2004","journal-title":"Acta Neurochir (Wien)"},{"key":"2020071611563648000_R56","first-page":"377","author":"Zervas","year":"1984"},{"key":"2020071611563648000_R57","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000180098","article-title":"Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors.","volume":"22","author":"Charpentier","year":"1985","journal-title":"Horm Res"},{"key":"2020071611563648000_R58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF01815444","volume":"8","author":"Fahlbusch","journal-title":"Neurosurg Rev"},{"key":"2020071611563648000_R59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0015-0282(16)45552-4","volume":"35","author":"Landolt","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R60","first-page":"108","volume":"58","author":"Randall","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R61","first-page":"161","article-title":"Prolactinomas: surgical therapy, indications and results.","volume":"14","author":"Rawe","year":"1980","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9378(79)90795-6","article-title":"Surgical treatment of prolactin-secreting microadenomas.","volume":"134","author":"Wiebe","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jcem-52-1-91","article-title":"Cure of hypogonadism after removal of prolactin-secreting adenomas in men.","volume":"52","author":"Arafah","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/jcem-59-1-79","article-title":"Return of gonadal function in men with prolactin-secreting pituitary tumors.","volume":"59","author":"Murray","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jama.1979.03300020028020","article-title":"Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea.","volume":"242","author":"Post","year":"1979","journal-title":"JAMA"},{"key":"2020071611563648000_R66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1210\/jcem-62-5-1044","article-title":"Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas.","volume":"62","author":"Stevenaert","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R67","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/acta.0.1070433","article-title":"Restoration of LH pulsatility in patients with prolactinomas after trans-sphenoidal surgery.","volume":"107","author":"Koizumi","year":"1984","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3171\/jns.1984.61.3.0577","article-title":"Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas.","volume":"61","author":"Nelson Jr","year":"1984","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R69","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bmj.291.6508.1547","article-title":"Management of selected patients with hyperprolactinaemia by partial hypophysectomy.","volume":"291","author":"Scanlon","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJM198308043090505","article-title":"Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.","volume":"309","author":"Serri","year":"1983","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2265.1990.tb00901.x","article-title":"Long-term follow-up of \u2018cured\u2019 prolactinoma patients after successful adenomectomy.","volume":"32","author":"Ciccarelli","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results.","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0090-3019(95)00430-0","article-title":"Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up.","volume":"45","author":"Massoud","year":"1996","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R74","first-page":"36","article-title":"Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up.","volume":"50","author":"Thomson","year":"2002","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R75","first-page":"73","author":"Hardy","year":"1984"},{"key":"2020071611563648000_R76","first-page":"128","article-title":"The neurosurgical management of prolactinomas.","volume":"44","author":"Gokalp","year":"2000","journal-title":"J Neurosurg Sci"},{"key":"2020071611563648000_R77","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0002-9343(87)90668-1","article-title":"Giant invasive prolactinomas.","volume":"83","author":"Murphy","year":"1987","journal-title":"Am J Med"},{"key":"2020071611563648000_R78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","article-title":"Giant prolactinomas: clinical management and long-term follow up.","volume":"97","author":"Shrivastava","year":"2002","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R79","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00701-002-0938-1","article-title":"Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.","volume":"144","author":"Kristof","year":"2002","journal-title":"Acta Neurochir (Wien)"},{"key":"2020071611563648000_R80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2265.1992.tb02900.x","article-title":"Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.","volume":"36","author":"Webster","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R81","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00701-003-0134-y","article-title":"Microprolactinomas in males treated by transsphenoidal surgery.","volume":"145","author":"Wolfsberger","year":"2003","journal-title":"Acta Neurochir (Wien)"},{"key":"2020071611563648000_R82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery.","volume":"97","author":"Amar","year":"2002","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R83","first-page":"1711","article-title":"Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long-term follow-up.","volume":"81","author":"Feigenbaum","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(82)92756-8","article-title":"Bromocriptine: does it jeopardise the result of later surgery for prolactinomas?","volume":"2","author":"Landolt","year":"1982","journal-title":"Lancet"},{"key":"2020071611563648000_R85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2265.1987.tb00809.x","article-title":"Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy.","volume":"26","author":"Bevan","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(83)91782-8","article-title":"Influence of previous bromocriptine therapy on surgery for microprolactinoma.","volume":"1","author":"Faglia","year":"1983","journal-title":"Lancet"},{"key":"2020071611563648000_R87","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0140-6736(84)92596-0","article-title":"Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma.","volume":"2","author":"Fahlbusch","year":"1984","journal-title":"Lancet"},{"key":"2020071611563648000_R88","first-page":"11","article-title":"Surgical results in microadenomas.","volume":"65","author":"Giovanelli","year":"1996","journal-title":"Acta Neurochir Suppl"},{"key":"2020071611563648000_R89","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1227\/00006123-198306000-00008","article-title":"Bromocriptine treatment of prolactin-secreting tumors: surgical implications.","volume":"12","author":"Weiss","year":"1983","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R90","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1210\/jc.2003-030461","article-title":"Transsphenoidal surgery for pituitary tumors in the United States, 1996\u20132000: mortality, morbidity, and the effects of hospital and surgeon volume.","volume":"88","author":"Barker 2nd","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R91","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/02688690400012459a","article-title":"Complications after trans-sphenoidal surgery: our experience and a review of the literature.","volume":"18","author":"Sudhakar","year":"2004","journal-title":"Br J Neurosurg"},{"key":"2020071611563648000_R92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1400043","article-title":"Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?","volume":"140","author":"Turner","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1227\/00006123-198509000-00008","article-title":"Visual recovery after transsphenoidal removal of pituitary adenomas.","volume":"17","author":"Cohen","year":"1985","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1227\/00006123-199007000-00008","article-title":"Loss of vision after transsphenoidal surgery.","volume":"27","author":"Barrow","year":"1990","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1042-3680(02)00090-6","article-title":"Role of surgery in the treatment of microprolactinomas.","volume":"14","author":"Couldwell","year":"2003","journal-title":"Neurosurg Clin N Am"},{"key":"2020071611563648000_R96","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2001-33619","article-title":"Is there a role for surgery for microprolactinomas?","volume":"12","author":"Wang","year":"2001","journal-title":"Semin Neurosurg"},{"key":"2020071611563648000_R97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","article-title":"Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.","volume":"63","author":"Biswas","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R98","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R99","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/B:PITU.0000044631.89535.48","article-title":"Medical and surgical management of microprolactinoma.","volume":"7","author":"Couldwell","year":"2004","journal-title":"Pituitary"},{"key":"2020071611563648000_R100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/B:PITU.0000004801.95086.e2","article-title":"Radiotherapy for non-functioning pituitary tumors\u2014when and under what circumstances?","volume":"6","author":"Gittoes","year":"2003","journal-title":"Pituitary"},{"key":"2020071611563648000_R101","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00024677-200403040-00002","article-title":"Stereotactic linear accelerator radiotherapy for pituitary tumors.","volume":"3","author":"Ajithkumar","year":"2004","journal-title":"Treat Endocrinol"},{"key":"2020071611563648000_R102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1042-3680(18)30190-6","article-title":"Linear accelerator radiosurgery in brain tumor management.","volume":"10","author":"Foote","year":"1999","journal-title":"Neurosurg Clin N Am"},{"key":"2020071611563648000_R103","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2265.2004.02138.x","article-title":"Radiosurgery for pituitary adenomas.","volume":"61","author":"Brada","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10143-005-0376-7","article-title":"Linac radiosurgery as a tool in neurosurgery.","volume":"28","author":"Deinsberger","year":"2005","journal-title":"Neurosurg Rev"},{"key":"2020071611563648000_R105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1042-3680(18)30092-5","article-title":"Linear accelerator radiosurgery for skull base tumors.","volume":"11","author":"Friedman","year":"2000","journal-title":"Neurosurg Clin N Am"},{"key":"2020071611563648000_R106","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0360-3016(99)00234-5","article-title":"Dosimetric comparison of three photon radiosurgery techniques for an elongated ellipsoid target.","volume":"45","author":"Yu","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/B:NEON.0000041887.51906.b7","article-title":"Stereotactic radiosurgery for pituitary adenomas: a review of the literature.","volume":"69","author":"Laws","year":"2004","journal-title":"J Neurooncol"},{"key":"2020071611563648000_R108","first-page":"284","article-title":"Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.","volume":"49","author":"Hoybye","year":"2001","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R109","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0360-3016(91)90005-O","article-title":"External irradiation of growth hormone producing pituitary adenomas: prolactin as a marker of hypothalamic and pituitary effects.","volume":"20","author":"Trampe","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0360-3016(90)90160-L","article-title":"Radiotherapy in the treatment of pituitary tumors.","volume":"19","author":"Plowman","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9343(86)90299-8","article-title":"Hypopituitarism following radiation therapy of pituitary adenomas.","volume":"81","author":"Snyder","year":"1986","journal-title":"Am J Med"},{"key":"2020071611563648000_R112","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1012926022229","article-title":"The role of gamma knife radiosurgery in the management of pituitary adenomas.","volume":"54","author":"Thoren","year":"2001","journal-title":"J Neurooncol"},{"key":"2020071611563648000_R113","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3171\/foc.2003.14.5.11","article-title":"Stereotactic radiosurgery for pituitary tumors","volume":"14","author":"Witt","year":"2003","journal-title":"Neurosurg Focus"},{"key":"2020071611563648000_R114","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ana.410020210","article-title":"Prolactin-secreting pituitary tumors.","volume":"2","author":"Antunes","year":"1977","journal-title":"Ann Neurol"},{"key":"2020071611563648000_R115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM197810192991602","article-title":"Prolactin-screening tumors and hypogonadism in 22 men.","volume":"299","author":"Carter","year":"1978","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R116","first-page":"648","article-title":"Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases.","volume":"62","author":"Gomez","year":"1977","journal-title":"Am J Med"},{"key":"2020071611563648000_R117","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.288.6424.1105","article-title":"Treatment of prolactinomas with megavoltage radiotherapy.","volume":"288","author":"Grossman","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R118","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2265.1986.tb01664.x","article-title":"The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.","volume":"24","author":"Johnston","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM197703172961103","article-title":"Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.","volume":"296","author":"Kleinberg","year":"1977","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(87)90496-7","article-title":"Primary radiotherapy of prolactinomas. Eight- to 15-year follow-up.","volume":"83","author":"Mehta","year":"1987","journal-title":"Am J Med"},{"key":"2020071611563648000_R121","author":"Sheline","year":"1984"},{"key":"2020071611563648000_R122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2265.1991.tb00312.x","article-title":"Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up.","volume":"34","author":"Tsagarakis","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-8140(96)91807-1","article-title":"Role of radiation therapy in clinical hormonally-active pituitary adenomas.","volume":"41","author":"Tsang","year":"1996","journal-title":"Radiother Oncol"},{"key":"2020071611563648000_R124","first-page":"50","article-title":"Treatment of macroprolactinomas at Auckland Hospital 1975\u201391.","volume":"108","author":"Wallace","year":"1995","journal-title":"N Z Med J"},{"key":"2020071611563648000_R125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","article-title":"Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.","volume":"27","author":"Wang","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0360-3016(95)00071-6","article-title":"External radiotherapy of pituitary adenomas.","volume":"33","author":"Zierhut","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R127","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0360-3016(98)00256-9","article-title":"Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas.","volume":"42","author":"Mitsumori","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R128","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijrobp.2004.09.058","article-title":"Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients.","volume":"62","author":"Colin","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3349\/ymj.2003.44.4.602","article-title":"Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery.","volume":"44","author":"Choi","year":"2003","journal-title":"Yonsei Med J"},{"key":"2020071611563648000_R130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3171\/jns.2002.97.supplement_5.0415","article-title":"Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function.","volume":"97","author":"Feigl","year":"2002","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R131","first-page":"30","article-title":"The effects of gamma knife surgery of pituitary adenomas on tumor growth and endocrinopathies","volume":"61","author":"Ganz","year":"1993","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000056446","article-title":"gamma knife radiosurgery for pituitary adenomas","volume":"72","author":"Hayashi","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000056448","article-title":"Pituitary adenomas treated by microsurgery with or without gamma knife surgery: experience in 122 cases","volume":"72","author":"Inoue","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 3","key":"2020071611563648000_R134","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3171\/jns.2000.93.supplement_3.0019","article-title":"Gamma knife radiosurgery for pituitary adenomas","volume":"93","author":"Izawa","year":"2000","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000056447","article-title":"Gamma knife radiosurgery for functioning pituitary microadenoma","volume":"72","author":"Kim","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R136","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000056445","article-title":"Gamma knife radiosurgery for functioning pituitary adenomas","volume":"72","author":"Kim","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"key":"2020071611563648000_R137","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1227\/01.NEU.0000124750.13721.94","article-title":"Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes.","volume":"54","author":"Kuo","year":"2004","journal-title":"Neurosurgery"},{"issue":"Suppl 3","key":"2020071611563648000_R138","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt","year":"2000","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R139","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1042-3680(18)30198-0","article-title":"Radiosurgery for pituitary tumors and craniopharyngiomas.","volume":"10","author":"Laws Jr","year":"1999","journal-title":"Neurosurg Clin N Am"},{"key":"2020071611563648000_R140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000099553","article-title":"Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients.","volume":"57","author":"Levy","year":"1991","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R141","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000056412","article-title":"Four years\u2019 experiences in the treatment of pituitary adenomas with gamma knife radiosurgery","volume":"70","author":"Lim","year":"1998","journal-title":"Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R142","first-page":"110","article-title":"Pituitary tumors and gamma knife surgery","volume":"70","author":"Martinez","year":"1998","journal-title":"Clinical experience with more than two years of follow-up. Stereotact Funct Neurosurg"},{"issue":"Suppl 1","key":"2020071611563648000_R143","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000056444","article-title":"A six year experience with the postoperative radiosurgical management of pituitary adenomas","volume":"72","author":"Mokry","year":"1999","journal-title":"Stereotact Funct Neurosurg"},{"key":"2020071611563648000_R144","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s007010050121","article-title":"Gamma-knife surgery for secreting pituitary adenomas.","volume":"140","author":"Morange-Ramos","year":"1998","journal-title":"Acta Neurochir (Wien)"},{"key":"2020071611563648000_R145","first-page":"225","article-title":"[Clinical results of LINAC-based stereotactic radiosurgery for pituitary adenoma].","volume":"63","author":"Muramatsu","year":"2003","journal-title":"Nippon Igaku Hoshasen Gakkai Zasshi"},{"issue":"Suppl 3","key":"2020071611563648000_R146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.2000.93.supplement_3.0010","article-title":"Gamma knife radiosurgery as a primary treatment for prolactinomas","volume":"93","author":"Pan","year":"2000","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R147","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1227\/01.NEU.0000068702.00330.47","article-title":"Gamma knife radiosurgery for pituitary adenoma: early results.","volume":"53","author":"Petrovich","year":"2003","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R148","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3171\/jns.2002.97.3.0525","article-title":"Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization.","volume":"97","author":"Pollock","year":"2002","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R149","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0360-3016(98)00124-2","article-title":"Clinical results of 24 pituitary macroadenomas with linac-based stereotactic radiosurgery.","volume":"41","author":"Yoon","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R150","first-page":"109","article-title":"Stereotactic radiosurgery: the Lyon experience.","volume":"63","author":"Rocher","year":"1995","journal-title":"Acta Neurochir Suppl"},{"key":"2020071611563648000_R151","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3171\/jns.1998.88.1.0043","article-title":"Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery.","volume":"88","author":"Leber","year":"1998","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R152","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0360-3016(93)90230-S","article-title":"Tolerance of cranial nerves of the cavernous sinus to radiosurgery.","volume":"27","author":"Tishler","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R153","first-page":"1022","article-title":"Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications.","volume":"48","author":"Chen","year":"2001","journal-title":"Neurosurgery"},{"issue":"Suppl 3","key":"2020071611563648000_R154","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3171\/jns.2000.93.supplement_3.0002","article-title":"Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus","volume":"93","author":"Shin","year":"2000","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0360-3016(89)90082-5","article-title":"An integrated logistic formula for prediction of complications from radiosurgery.","volume":"17","author":"Flickinger","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R156","first-page":"145","article-title":"Hypopituitarism following external radiotherapy for pituitary tumours in adults.","volume":"70","author":"Littley","year":"1989","journal-title":"Q J Med"},{"key":"2020071611563648000_R157","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0360-3016(92)90941-A","article-title":"Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors.","volume":"30","author":"Tsang","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R158","doi-asserted-by":"crossref","first-page":"771","DOI":"10.7326\/0003-4819-83-6-771","article-title":"Hypopituitarism after external irradiation. Evidence for both hypothalamic and pituitary origin.","volume":"83","author":"Samaan","year":"1975","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R159","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"key":"2020071611563648000_R160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00066-002-0826-x","article-title":"Radiation therapy in the multimodal treatment approach of pituitary adenoma.","volume":"178","author":"Becker","year":"2002","journal-title":"Strahlenther Onkol"},{"key":"2020071611563648000_R161","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0360-3016(99)00159-5","article-title":"The incidence of cerebrovascular accidents in patients with pituitary adenoma.","volume":"45","author":"Brada","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071611563648000_R162","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3171\/jns.1990.72.4.0594","article-title":"Neuro-ophthalmological assessment of vision before and after radiation therapy alone for pituitary macroadenomas.","volume":"72","author":"Rush","year":"1990","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R163","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2265.2001.01385.x","article-title":"Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?","volume":"55","author":"Erfurth","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R164","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2004-1152","article-title":"Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.","volume":"90","author":"Minniti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R165","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I","article-title":"Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk.","volume":"72","author":"Tsang","year":"1993","journal-title":"Cancer"},{"key":"2020071611563648000_R166","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3171\/jns.2005.102.4.0678","article-title":"Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium.","volume":"102","author":"Sheehan","year":"2005","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R167","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0014-827X(99)00028-2","article-title":"Ergoline derivatives: receptor affinity and selectivity.","volume":"54","author":"Mantegani","year":"1999","journal-title":"Farmaco"},{"key":"2020071611563648000_R168","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1358\/dof.1988.013.10.70082","article-title":"Endocrine actions of the potent dopamine D2-agonist CV 205\u2013502 and related octrahydrobenzo(g)quinolones.","volume":"13","author":"Nordmann","year":"1988","journal-title":"Drugs of the Future"},{"key":"2020071611563648000_R169","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/jm00381a017","article-title":"Octahydrobenzo (g) quinolones: potent dopamine agonists which show the relationship between ergolines and apomorphine.","volume":"28","author":"Nordmann","year":"1985","journal-title":"J Med Chem"},{"key":"2020071611563648000_R170","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1021\/jm00148a030","article-title":"Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N\u2032-[(3a,4aa,10ab)-1,2,3,4,4a,5,10,10a,-octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl] sulfamide.","volume":"28","author":"Nordmann","year":"1985","journal-title":"J Med Chem"},{"key":"2020071611563648000_R171","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/0024-3205(88)90301-3","article-title":"Hormonal effects of CV 205\u2013502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties.","volume":"43","author":"Gaillard","year":"1988","journal-title":"Life Sci"},{"key":"2020071611563648000_R172","author":"Gaillard","year":"1985"},{"key":"2020071611563648000_R173","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0006-8993(88)91164-X","article-title":"In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205\u2013502.","volume":"440","author":"Closse","year":"1988","journal-title":"Brain Res"},{"key":"2020071611563648000_R174","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/acta.0.1160287","article-title":"Effects of two novel dopaminergic drugs, CV 205\u2013502 and CQP 201\u2013403, on prolactin and growth hormone secretion by human pituitary tumours in vitro.","volume":"116","author":"Venetikou","year":"1987","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/13543784.11.6.787","article-title":"Dopamine receptor agonists for treating prolactinomas.","volume":"11","author":"Colao","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"2020071611563648000_R176","first-page":"576","article-title":"Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.","volume":"23","author":"Enjalbert","year":"1983","journal-title":"Mol Pharmacol"},{"key":"2020071611563648000_R177","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0165-6147(89)90082-5","article-title":"Mechanisms of signal transduction at the dopamine D2 receptor.","volume":"10","author":"Vallar","year":"1989","journal-title":"Trends Pharmacol Sci"},{"key":"2020071611563648000_R178","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2265.1991.tb00928.x","article-title":"Dopamine, the dopamine D2 receptor and pituitary tumours.","volume":"35","author":"Wood","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R179","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000182494","article-title":"D2 dopaminergic receptors: normal and abnormal transduction mechanisms.","volume":"38","author":"Caccavelli","year":"1992","journal-title":"Horm Res"},{"key":"2020071611563648000_R180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/336783a0","article-title":"Cloning and expression of a rat D2 dopamine receptor cDNA.","volume":"336","author":"Bunzow","year":"1988","journal-title":"Nature"},{"key":"2020071611563648000_R181","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/342923a0","article-title":"Alternative splicing directs the expression of two D2 dopamine receptor isoforms.","volume":"342","author":"Giros","year":"1989","journal-title":"Nature"},{"key":"2020071611563648000_R182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-56-1-1","article-title":"In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide.","volume":"56","author":"Spada","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R183","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function.","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol Rev"},{"key":"2020071611563648000_R184","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage.","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"2020071611563648000_R185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/endo.134.1.7903933","article-title":"Inhibitory effects of the dopamine agonists quinagolide (CV 205\u2013502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.","volume":"134","author":"Trouillas","year":"1994","journal-title":"Endocrinology"},{"key":"2020071611563648000_R186","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM198509123131103","article-title":"Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.","volume":"313","author":"Liuzzi","year":"1985","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R187","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R188","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","article-title":"Drugs five years later. Bromocriptine.","volume":"100","author":"Vance","year":"1984","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R189","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","article-title":"Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?","volume":"58","author":"Landolt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R190","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea.","volume":"315","author":"Klibanski","year":"1986","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R191","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.","volume":"83","author":"Di Somma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R192","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","article-title":"Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.","volume":"138","author":"De Rosa","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R193","first-page":"275","article-title":"Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.","volume":"75","author":"Beckers","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R194","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.1990.tb00479.x","article-title":"Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).","volume":"33","author":"Schettini","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/acta.0.1190051","article-title":"Primary treatment of macroprolactinomas with Parlodel LAR.","volume":"119","author":"Verlaat","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R196","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1507\/endocrj.42.413","article-title":"Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.","volume":"42","author":"Eguchi","year":"1995","journal-title":"Endocr J"},{"key":"2020071611563648000_R197","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1507\/endocrj.42.153","article-title":"In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.","volume":"42","author":"Eguchi","year":"1995","journal-title":"Endocr J"},{"key":"2020071611563648000_R198","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1987.tb03072.x","article-title":"Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3\u2032-dimethylaminopropyl)-3-(6\u2032-allylergoline-8\u2032-\u03b2- carbonyl)-urea-diphosphate (FCE 21336).","volume":"23","author":"Pontiroli","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"2020071611563648000_R199","first-page":"841","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.","volume":"80","author":"Andreotti","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1210\/jcem-65-3-541","article-title":"Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.","volume":"65","author":"Melis","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R201","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/14656566.1.3.555","article-title":"Cabergoline.","volume":"1","author":"Colao","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"2020071611563648000_R202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","article-title":"The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.","volume":"39","author":"Webster","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R203","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R204","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R205","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R206","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R207","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R208","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(81)90997-1","article-title":"Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.","volume":"2","author":"Franks","year":"1981","journal-title":"Lancet"},{"key":"2020071611563648000_R209","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1980.91","article-title":"Pergolide, a potent long-acting dopamine-receptor agonist.","volume":"27","author":"Lemberger","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"2020071611563648000_R210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1530\/acta.0.1010481","article-title":"Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women.","volume":"101","author":"L\u2019Hermite","year":"1982","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R211","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1210\/jcem-53-4-772","article-title":"Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.","volume":"53","author":"Perryman","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R212","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson\u2019s disease.","volume":"39","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"2020071611563648000_R213","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","article-title":"A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.","volume":"72","author":"Lamberts","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R214","first-page":"421","article-title":"The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.","volume":"15","author":"Bergh","year":"1984","journal-title":"Acta Eur Fertil"},{"key":"2020071611563648000_R215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2265.1985.tb02996.x","article-title":"Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.","volume":"22","author":"Grossman","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R216","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bmj.285.6340.465","article-title":"Reduction in size of prolactin-secreting tumours in men treated with pergolide.","volume":"285","author":"Kendall-Taylor","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R217","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM198309223091205","article-title":"Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.","volume":"309","author":"Kleinberg","year":"1983","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R218","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1210\/jcem.85.1.6329","article-title":"Long-term treatment of prolactin-secreting macroadenomas with pergolide.","volume":"85","author":"Freda","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R219","first-page":"415","article-title":"Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.","volume":"4","author":"Horowitz","year":"1983","journal-title":"AJNR Am J Neuroradiol"},{"key":"2020071611563648000_R220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0015-0282(16)47111-6","article-title":"Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.","volume":"39","author":"Blackwell","year":"1983","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R221","first-page":"375","article-title":"Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.","volume":"27","author":"Berezin","year":"1991","journal-title":"Isr J Med Sci"},{"key":"2020071611563648000_R222","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1012836331506","article-title":"Pergolide as primary therapy for macroprolactinomas.","volume":"3","author":"Orrego","year":"2000","journal-title":"Pituitary"},{"key":"2020071611563648000_R223","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/BF03347910","article-title":"CV 205\u2013502 treatment of macroprolactinomas.","volume":"14","author":"Crottaz","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R224","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","article-title":"Effect of the new dopaminergic agonist CV 205\u2013502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.","volume":"34","author":"Duranteau","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R226","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205\u2013502, with bromocriptine in women with hyperprolactinaemia.","volume":"32","author":"Homburg","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R227","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2265.1989.tb01263.x","article-title":"Effect of CV 205\u2013502 in hyperprolactinaemic patients intolerant of bromocriptine.","volume":"31","author":"Newman","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R228","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","article-title":"The efficacy and tolerability of CV 205\u2013502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.","volume":"72","author":"Lely","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R229","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7326\/0003-4819-112-9-668","article-title":"Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205\u2013502.","volume":"112","author":"Vance","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R230","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","article-title":"Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.","volume":"41","author":"Vilar","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R231","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205\u2013502 restores the gonadal function in hyperprolactinemic males.","volume":"135","author":"Colao","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R232","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF03343751","article-title":"A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.","volume":"23","author":"De Luis","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R233","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03344963","article-title":"A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.","volume":"17","author":"Giusti","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R234","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1210\/endo-98-3-598","article-title":"Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.","volume":"98","author":"Graf","year":"1976","journal-title":"Endocrinology"},{"key":"2020071611563648000_R235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jcem-46-2-196","article-title":"Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.","volume":"46","author":"Liuzzi","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R236","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1471-0528.1979.tb10722.x","article-title":"Effect of lisuride on inhibition of lactation and serum prolactin.","volume":"86","author":"De Cecco","year":"1979","journal-title":"Br J Obstet Gynaecol"},{"key":"2020071611563648000_R237","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1210\/jcem-63-4-1002","article-title":"Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.","volume":"63","author":"Dallabonzana","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R238","first-page":"53","article-title":"Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women.","volume":"71","author":"Bohnet","year":"1988","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R239","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/bmj.1.6063.744","article-title":"Metergoline in the inhibition of puerperal lactation.","volume":"1","author":"Delitala","year":"1977","journal-title":"Br Med J"},{"key":"2020071611563648000_R240","first-page":"113","article-title":"Suppression of puerperal lactation by metergoline.","volume":"51","author":"Crosignani","year":"1978","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R241","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9378(78)90898-0","article-title":"Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine.","volume":"132","author":"Crosignani","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R242","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00006250-198602000-00016","article-title":"Treatment of hyperprolactinemic amenorrhea with ;Metergoline.","volume":"67","author":"Bohnet","year":"1986","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R243","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJM198003273021313","article-title":"Side effects of bromocriptine.","volume":"302","author":"Kissner","year":"1980","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R244","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf"},{"key":"2020071611563648000_R245","first-page":"317","author":"Dutz","year":"1992"},{"key":"2020071611563648000_R246","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(76)99036-X","article-title":"Letter: Digital vasospasm with bromocriptine.","volume":"1","author":"Wass","year":"1976","journal-title":"Lancet"},{"key":"2020071611563648000_R247","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1288\/00005537-199310000-00011","article-title":"Nasal mucosal congestion after treatment with bromocriptine.","volume":"103","author":"Bende","year":"1993","journal-title":"Laryngoscope"},{"key":"2020071611563648000_R248","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/bmj.1.6111.510-a","article-title":"Bromocriptine-induced mania?","volume":"1","author":"Vlissides","year":"1978","journal-title":"Br Med J"},{"key":"2020071611563648000_R249","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/bmj.285.6351.1315","article-title":"Bromocriptine-induced psychosis in acromegaly.","volume":"285","author":"Le Feuvre","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198107163050321","article-title":"Mental disorders from low-dose bromocriptine.","volume":"305","author":"Pearson","year":"1981","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R251","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.289.6452.1101","article-title":"Psychotic reactions during treatment of pituitary tumours with dopamine agonists.","volume":"289","author":"Turner","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R252","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004714-198912000-00006","article-title":"The behavioral toxicity of bromocriptine in patients with psychiatric illness.","volume":"9","author":"Perovich","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"2020071611563648000_R253","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease.","volume":"18","author":"Paus","year":"2003","journal-title":"Mov Disord"},{"key":"2020071611563648000_R254","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0090-3019(82)90020-9","article-title":"Bromocriptine-induced cerebrospinal fluid rhinorrhea.","volume":"18","author":"Afshar","year":"1982","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R255","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJM197906143002411","article-title":"Bromocriptine treatment of prolactinomas.","volume":"300","author":"Aronoff","year":"1979","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R256","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJM198201213060322","article-title":"CSF rhinorrhea after bromocriptine for prolactinoma.","volume":"306","author":"Baskin","year":"1982","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R257","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.35.8.1193","article-title":"Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma.","volume":"35","author":"Kok","year":"1985","journal-title":"Neurology"},{"key":"2020071611563648000_R258","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1227\/00006123-198209000-00010","article-title":"Cerebrospinal fluid rhinorrhea: a complication of therapy for invasive prolactinomas.","volume":"11","author":"Landolt","year":"1982","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R259","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2265.2000.00901.x","article-title":"CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.","volume":"52","author":"Leong","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(93)90160-Q","article-title":"Edema\u2014an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs.","volume":"94","author":"Blackard","year":"1993","journal-title":"Am J Med"},{"key":"2020071611563648000_R261","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/clc.4960151019","article-title":"Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.","volume":"15","author":"Eickman","year":"1992","journal-title":"Clin Cardiol"},{"key":"2020071611563648000_R262","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000441-198105000-00008","article-title":"Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration.","volume":"281","author":"Giampietro","year":"1981","journal-title":"Am J Med Sci"},{"key":"2020071611563648000_R263","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-118-3-199302010-00008","article-title":"Possible bromocriptine-induced myocardial infarction.","volume":"118","author":"Larrazet","year":"1993","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R264","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/bmj.285.6354.1534","article-title":"Bromocriptine-associated hyponatraemia in cirrhosis.","volume":"285","author":"Marshall","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003495-199549020-00009","article-title":"Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"2020071611563648000_R266","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.302.6789.1367","volume":"302","journal-title":"BMJ"},{"key":"2020071611563648000_R267","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410300416","article-title":"Pleuropulmonary disease associated with dopamine agonist therapy.","volume":"30","author":"Bhatt","year":"1991","journal-title":"Ann Neurol"},{"key":"2020071611563648000_R268","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1183\/09031936.93.05020263","article-title":"Pleuropulmonary changes during treatment of Parkinson\u2019s disease with a long-acting ergot derivative, cabergoline.","volume":"5","author":"Frans","year":"1992","journal-title":"Eur Respir J"},{"key":"2020071611563648000_R269","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejim.2004.09.014","article-title":"Pleural effusion and thickening due to cabergoline use in a patient with Parkinson\u2019s disease.","volume":"16","author":"Guptha","year":"2005","journal-title":"Eur J Intern Med"},{"key":"2020071611563648000_R270","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/74.4.371","article-title":"Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson\u2019s disease.","volume":"74","author":"Ling","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R271","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"2020071611563648000_R272","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation.","volume":"353","author":"Pinero","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R273","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R274","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R275","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0002-9378(86)90685-X","article-title":"Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.","volume":"154","author":"Kletzky","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R276","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.62.8.1242","article-title":"Sudden uncontrollable somnolence and medication use in Parkinson disease.","volume":"62","author":"Avorn","year":"2005","journal-title":"Arch Neurol"},{"key":"2020071611563648000_R277","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/01.WNL.0000044058.64647.7E","article-title":"Tic reduction with pergolide in a randomized controlled trial in children.","volume":"60","author":"Gilbert","year":"2003","journal-title":"Neurology"},{"key":"2020071611563648000_R278","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4065\/78.6.684","article-title":"Additional insights into pergolide-associated valvular heart disease.","volume":"78","author":"Lanier","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R279","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide.","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R280","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson\u2019s disease treated with high-dose pergolide.","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"2020071611563648000_R281","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","article-title":"The US Food and Drug Administration\u2019s registry of patients with pergolide-associated valvular heart disease.","volume":"78","author":"Flowers","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R282","first-page":"577","article-title":"Effects of the dopamine agonist CV 205\u2013502 in human prolactinomas resistant to bromocriptine.","volume":"74","author":"Brue","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R283","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1530\/acta.0.1250170","article-title":"Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205\u2013502.","volume":"125","author":"Rasmussen","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R284","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0015-0282(16)54175-2","article-title":"CV 205\u2013502\u2013effectiveness, tolerability, and safety over 24-month study.","volume":"55","author":"Shoham","year":"1991","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R285","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1210\/jcem-68-2-336","article-title":"CV 205\u2013502 treatment of hyperprolactinemia.","volume":"68","author":"Vance","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R286","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2265.1993.tb00351.x","article-title":"Intracranial dissemination of a macroprolactinoma.","volume":"38","author":"Assies","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R287","first-page":"891","article-title":"Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205\u2013502.","volume":"81","author":"Barnett","year":"1991","journal-title":"Q J Med"},{"key":"2020071611563648000_R288","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","article-title":"CV 205\u2013502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.","volume":"40","author":"Heijden","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071611563648000_R289","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0015-0282(16)60966-4","article-title":"The effectiveness, safety, and tolerability of CV 205\u2013502 in hyperprolactinemic women: a 12-month study.","volume":"52","author":"Heijden","year":"1989","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026225625897","article-title":"Dopamine resistance of prolactinomas.","volume":"6","author":"Molitch","year":"2003","journal-title":"Pituitary"},{"key":"2020071611563648000_R291","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1530\/eje.0.1340454","article-title":"Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.","volume":"134","author":"Delgrange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R292","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","article-title":"Resistance to bromocriptine in prolactinomas.","volume":"69","author":"Pellegrini","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R293","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients.","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"2020071611563648000_R294","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary.","volume":"112","author":"Melmed","year":"2003","journal-title":"J Clin Invest"},{"key":"2020071611563648000_R295","first-page":"568","article-title":"Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors.","volume":"78","author":"Friedman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R296","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1210\/jcem-51-5-1037","article-title":"Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.","volume":"51","author":"Bression","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R297","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1210\/endo-129-2-1101","article-title":"Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids.","volume":"129","author":"Kukstas","year":"1991","journal-title":"Endocrinology"},{"key":"2020071611563648000_R298","doi-asserted-by":"crossref","first-page":"7961","DOI":"10.1073\/pnas.90.17.7961","article-title":"Nerve growth factor suppresses the transforming phenotype of human prolactinomas.","volume":"90","author":"Missale","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611563648000_R299","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.7761832","article-title":"A region of adenylyl cyclase 2 critical for regulation by G protein \u03b2\u03b3-subunits.","volume":"268","author":"Chen","year":"1995","journal-title":"Science"},{"key":"2020071611563648000_R300","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev.pa.36.040196.002333","article-title":"Complexity and diversity of mammalian adenylyl cyclases.","volume":"36","author":"Sunahara","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2020071611563648000_R301","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"key":"2020071611563648000_R302","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3171\/jns.1995.82.5.0886","article-title":"Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report.","volume":"82","author":"Kovacs","year":"1995","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R303","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/jcem.85.1.6253","article-title":"Malignant prolactinoma discovered by D2 receptor imaging.","volume":"85","author":"Petrossians","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R304","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1210\/endo.139.10.6246","article-title":"Alternative splicing of the D2 dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line.","volume":"139","author":"Guivarc\u2019h","year":"1998","journal-title":"Endocrinology"},{"key":"2020071611563648000_R305","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1074\/jbc.M309792200","article-title":"A region of the third intracellular loop of the short form of the D2 dopamine receptor dictates Gi coupling specificity.","volume":"279","author":"Senogles","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071611563648000_R306","doi-asserted-by":"crossref","first-page":"23120","DOI":"10.1016\/S0021-9258(17)31628-9","article-title":"The D2 dopamine receptor isoforms signal through distinct Gi \u03b1 proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi \u03b1 proteins.","volume":"269","author":"Senogles","year":"1994","journal-title":"J Biol Chem"},{"key":"2020071611563648000_R307","first-page":"920","article-title":"Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line.","volume":"6","author":"Hayes","year":"1992","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R308","first-page":"161","article-title":"Preferential coupling between dopamine D2 receptors and G-proteins.","volume":"7","author":"Montmayeur","year":"1993","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R309","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000185468","article-title":"Abnormal transduction mechanisms in pituitary adenomas.","volume":"47","author":"Barlier","year":"1997","journal-title":"Horm Res"},{"key":"2020071611563648000_R310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0303-7207(91)90183-S","article-title":"G proteins in normal rat pituitaries and in prolactin-secreting rat pituitary tumors.","volume":"78","author":"Bouvier","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"2020071611563648000_R311","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1210\/endo-122-3-1176","article-title":"Selective deficiency of guanine nucleotide-binding protein Go in two dopamine-resistant pituitary tumors.","volume":"122","author":"Collu","year":"1988","journal-title":"Endocrinology"},{"key":"2020071611563648000_R312","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2826.1996.04902.x","article-title":"Alteration of G \u03b1-subunit mRNA levels in bromocriptine resistant prolactinomas.","volume":"8","author":"Caccavelli","year":"1996","journal-title":"J Neuroendocrinol"},{"key":"2020071611563648000_R313","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/frne.1998.0165","article-title":"Nerve growth factor in pituitary development and pituitary tumors.","volume":"19","author":"Missale","year":"1998","journal-title":"Front Neuroendocrinol"},{"key":"2020071611563648000_R314","first-page":"272","article-title":"Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism.","volume":"10","author":"Missale","year":"1996","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R315","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/bjc.1995.520","article-title":"Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.","volume":"72","author":"Missale","year":"1995","journal-title":"Br J Cancer"},{"key":"2020071611563648000_R316","first-page":"353","article-title":"Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-\u03baB.","volume":"16","author":"Fiorentini","year":"2002","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R317","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1210\/me.2003-0190","article-title":"Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase.","volume":"18","author":"Facchetti","year":"2004","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R318","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF03350560","article-title":"Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases.","volume":"6","author":"Dallabonzana","year":"1983","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R319","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bmj.287.6390.451","article-title":"Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.","volume":"287","author":"Breidahl","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020071611563648000_R320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/eje.0.1460081","article-title":"Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report.","volume":"146","author":"Winkelmann","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R321","first-page":"250","article-title":"Late development of resistance to bromocriptine in a patient with macroprolactinoma.","volume":"49","author":"Delgrange","year":"1998","journal-title":"Horm Res"},{"key":"2020071611563648000_R322","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1210\/jcem.82.9.4217","article-title":"Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression.","volume":"82","author":"Hurel","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R323","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R324","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0014-2999(90)90367-F","article-title":"In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.","volume":"187","author":"Benedetti","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"2020071611563648000_R325","first-page":"753","article-title":"[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].","volume":"24","author":"Pascal-Vigneron","year":"1995","journal-title":"Presse Med"},{"key":"2020071611563648000_R326","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513599409072452","article-title":"Positive response to compound CV 205\u2013502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.","volume":"8","author":"Merola","year":"1994","journal-title":"Gynecol Endocrinol"},{"key":"2020071611563648000_R327","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.","volume":"135","author":"Morange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R328","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000182739","article-title":"The effects of CV205\u2013502 in patients with hyperprolactinaemia intolerant and\/or resistant to bromocriptine.","volume":"39","author":"Razzaq","year":"1993","journal-title":"Horm Res"},{"key":"2020071611563648000_R329","first-page":"411","article-title":"Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l\u2019Hypophyse.","volume":"61","author":"Rohmer","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"2020071611563648000_R330","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1986.tb01647.x","article-title":"Discordant responses of prolactinoma to two different dopamine agonists.","volume":"24","author":"Ahmed","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R331","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.","volume":"87","author":"Gillam","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R332","first-page":"708","article-title":"Spontaneous and induced pregnancies in hyperprolactinemic women.","volume":"58","author":"Crosignani","year":"1981","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R333","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02108310","article-title":"Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea.","volume":"229","author":"Leyendecker","year":"1980","journal-title":"Arch Gynecol"},{"key":"2020071611563648000_R334","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)44178-6","article-title":"Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine.","volume":"32","author":"Radwanska","year":"1979","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R335","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.","volume":"87","author":"Losa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R336","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jcem-62-6-1296","article-title":"Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.","volume":"62","author":"Schlechte","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R337","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0002-9343(83)90418-7","article-title":"Hyperprolactinemia. Long-term effects of bromocriptine.","volume":"75","author":"Johnston","year":"1983","journal-title":"Am J Med"},{"key":"2020071611563648000_R338","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2265.1982.tb03175.x","article-title":"Menstrual function and serum prolactin levels after long-term bromocriptine treatment of hyperprolactinaemic amenorrhoea.","volume":"16","author":"Bergh","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R339","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","article-title":"Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.","volume":"2","author":"Johnston","year":"1984","journal-title":"Lancet"},{"key":"2020071611563648000_R340","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","article-title":"Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.","volume":"41","author":"Maxson","year":"1984","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R341","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","article-title":"Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.","volume":"60","author":"Moriondo","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R342","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R343","first-page":"817","author":"Winkelmann","year":"1985"},{"key":"2020071611563648000_R344","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/acta.0.1040139","article-title":"Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.","volume":"104","author":"Zarate","year":"1983","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.","volume":"34","author":"Verlaat","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R346","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1210\/jcem-53-3-480","article-title":"Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.","volume":"53","author":"Thorner","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R347","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","article-title":"Cabergoline in the long-term therapy of hyperprolactinemic disorders.","volume":"126","author":"Ferrari","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R348","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.","volume":"20","author":"Muratori","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R349","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.","volume":"22","author":"Cannavo","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R350","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women.","volume":"44","author":"Crosignani","year":"1992","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071611563648000_R351","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia.","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R352","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia.","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R353","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R354","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","article-title":"Treatment of macroprolactinoma with cabergoline: a study of 85 patients.","volume":"46","author":"Ferrari","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000054574","article-title":"Differential regulation of prolactin release and lactotrope proliferation during pregnancy, lactation and the estrous cycle.","volume":"72","author":"Yin","year":"2000","journal-title":"Neuroendocrinology"},{"key":"2020071611563648000_R356","first-page":"183","article-title":"A comparative study of longitudinal and cross-sectional changes in plasma levels of prolactin and estriol during normal pregnancy.","volume":"19","author":"Ferriani","year":"1986","journal-title":"Braz J Med Biol Res"},{"key":"2020071611563648000_R357","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0002-9378(77)90594-4","article-title":"Pattern of increase in circulating prolactin levels during human gestation.","volume":"129","author":"Rigg","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R358","first-page":"64","article-title":"Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment.","volume":"39","author":"Dinc","year":"1998","journal-title":"Acta Radiol"},{"key":"2020071611563648000_R359","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiology.181.2.1924800","article-title":"Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging.","volume":"181","author":"Elster","year":"1991","journal-title":"Radiology"},{"key":"2020071611563648000_R360","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9343(88)80346-2","article-title":"Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging.","volume":"85","author":"Gonzalez","year":"1988","journal-title":"Am J Med"},{"key":"2020071611563648000_R361","first-page":"19","article-title":"Acute visual loss during pregnancy after bromocriptine-induced ovulation. The elusive tumor.","volume":"52","author":"Burry","year":"1978","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R362","first-page":"69","article-title":"Visual abnormalities in a pregnancy following bromocriptin medication.","volume":"50","author":"Corbey","year":"1977","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R363","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jnnp.38.9.919","article-title":"Visual failure from pituitary and parasellar tumours occurring with favourable outcome in pregnant women.","volume":"38","author":"Falconer","year":"1975","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020071611563648000_R364","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0015-0282(16)42314-9","article-title":"Conservative management of a pituitary tumor during pregnancy following induction of ovulation with gonadotropins.","volume":"28","author":"Jewelewicz","year":"1977","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R365","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/bmj.4.5779.88","article-title":"Emergency hypophysectomy in pregnancy after induction of ovulation.","volume":"4","author":"Kajtar","year":"1971","journal-title":"Br Med J"},{"key":"2020071611563648000_R366","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/jcem-44-1-180","volume":"44","author":"Lamberts","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R367","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3171\/jns.1978.49.2.0283","article-title":"Symptomatic pituitary tumor enlargement after induced pregnancy. Case report.","volume":"49","author":"Nelson","year":"1978","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R368","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/bmj.4.5779.90","article-title":"Visual disturbance in pregnancy after induction of ovulation.","volume":"4","author":"Swyer","year":"1971","journal-title":"Br Med J"},{"key":"2020071611563648000_R369","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9378(78)80008-8","article-title":"Pituitary tumors and pregnancy.","volume":"132","author":"Magyar","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R370","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0015-0282(16)43929-4","article-title":"Outcome of pregnancy in women with pituitary adenoma.","volume":"31","author":"Gemzell","year":"1979","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R371","doi-asserted-by":"crossref","first-page":"473","DOI":"10.7326\/0003-4819-121-7-199410010-00001","article-title":"Visual loss in pregnant women with pituitary adenomas.","volume":"121","author":"Kupersmith","year":"1994","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R372","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198505233122106","article-title":"Pregnancy and the hyperprolactinemic woman.","volume":"312","author":"Molitch","year":"1985","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R373","first-page":"91","author":"Musolino","year":"2001"},{"key":"2020071611563648000_R374","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0301-2115(95)02257-0","article-title":"Outcome of pregnancies in women with treated or untreated hyperprolactinemia.","volume":"63","author":"Rossi","year":"1995","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071611563648000_R375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1015319007880","article-title":"Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.","volume":"4","author":"Liu","year":"2001","journal-title":"Pituitary"},{"key":"2020071611563648000_R376","first-page":"117","article-title":"Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy.","volume":"61","author":"Maeda","year":"1983","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R377","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0015-0282(16)45674-8","article-title":"Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy.","volume":"36","author":"Roon","year":"1981","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R378","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1986.tb01698.x","article-title":"Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy.","volume":"25","author":"Belchetz","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R379","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bmj.1.6117.875","article-title":"Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumors.","volume":"1","author":"Bergh","year":"1978","journal-title":"Br Med J"},{"key":"2020071611563648000_R380","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1471-0528.1984.tb04859.x","article-title":"Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports.","volume":"91","author":"Crosignani","year":"1984","journal-title":"Br J Obstet Gynaecol"},{"key":"2020071611563648000_R381","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.2.6193.771","article-title":"Pregnancy in patients presenting with hyperprolactinaemia.","volume":"2","author":"Thorner","year":"1979","journal-title":"Br Med J"},{"key":"2020071611563648000_R382","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0020-7292(86)90099-8","article-title":"Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy.","volume":"24","author":"Tan","year":"1986","journal-title":"Int J Gynaecol Obstet"},{"key":"2020071611563648000_R383","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects.","volume":"65","author":"Krupp","year":"1987","journal-title":"Klin Wochenschr"},{"key":"2020071611563648000_R384","first-page":"9","volume-title":"Proc of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro","author":"Krupp","year":"1988"},{"key":"2020071611563648000_R385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000180100","article-title":"Follow-up of children born of bromocriptine-treated mothers.","volume":"22","author":"Raymond","year":"1985","journal-title":"Horm Res"},{"key":"2020071611563648000_R386","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/jcem-48-1-9","article-title":"A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments.","volume":"48","author":"Bigazzi","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R387","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/mds.10040","article-title":"Antiparkinsonian treatment in pregnancy.","volume":"17","author":"De Mari","year":"2002","journal-title":"Mov Disord"},{"key":"2020071611563648000_R388","article-title":"Review of pregnancy reports in patients on pergolide treatment.","author":"Acharya","year":"2004","journal-title":"Indianapolis"},{"key":"2020071611563648000_R389","author":"1997 Data on file"},{"key":"2020071611563648000_R390","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","article-title":"Pregnancy outcome after cabergoline treatment in early weeks of gestation.","volume":"16","author":"Ricci","year":"2002","journal-title":"Reprod Toxicol"},{"key":"2020071611563648000_R391","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline.","volume":"10","author":"Robert","year":"1996","journal-title":"Reprod Toxicol"},{"key":"2020071611563648000_R392","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R393","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3171\/jns.1983.58.5.0685","article-title":"Pregnancy following transsphenoidal resection of prolactin-secreting pituitary tumors.","volume":"58","author":"Laws Jr","year":"1983","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R394","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/0002-9378(86)90164-X","article-title":"Pregnancy after treatment in patients with prolactinoma: operation versus bromocriptine.","volume":"155","author":"Samaan","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R395","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ecl.2005.09.011","article-title":"Pituitary disorders during pregnancy.","volume":"35","author":"Molitch","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"Suppl A","key":"2020071611563648000_R396","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S1096-6374(03)00054-6","article-title":"Pituitary tumors and pregnancy","volume":"13","author":"Molitch","year":"2003","journal-title":"Growth Horm IGF Res"},{"key":"2020071611563648000_R397","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1530\/acta.0.1100440","article-title":"Pulsatile GnRH therapy\u2014an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours.","volume":"110","author":"Bergh","year":"1985","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R398","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0015-0282(16)49899-7","article-title":"Treatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin-releasing hormone therapy.","volume":"46","author":"Gindoff","year":"1986","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R399","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1471-0528.1978.tb14949.x","article-title":"Induction of ovulation with clomiphene and human chorionic gonadotrophin in women with hyperprolactinaemic amenorrhoea.","volume":"85","author":"McGarrigle","year":"1978","journal-title":"Br J Obstet Gynaecol"},{"key":"2020071611563648000_R400","first-page":"1507","volume":"83","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R401","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/j.1471-0528.2004.00275.x","article-title":"Pregnancy following monofollicular ovulation induction with recombinant FSH, recombinant LH and timed coitus in an amenorrheic woman with long-standing hypogonadotrophic hypogonadism.","volume":"111","author":"El-Shawarby","year":"2004","journal-title":"BJOG"},{"key":"2020071611563648000_R402","first-page":"758","article-title":"Relationship between maternal prolactin levels during pregnancy and lactation in women with pituitary adenoma.","volume":"37","author":"Narita","year":"1985","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"key":"2020071611563648000_R403","first-page":"425","article-title":"Prolactin-producing microadenomas in pregnancy.","volume":"62","author":"Divers Jr","year":"1983","journal-title":"Obstet Gynecol"},{"key":"2020071611563648000_R404","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0015-0282(16)47888-X","article-title":"Pregnancy in hyperprolactinemic women.","volume":"41","author":"Ruiz-Velasco","year":"1984","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R405","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0002-9378(16)32785-5","article-title":"Surgery during pregnancy and fetal outcome.","volume":"138","author":"Brodsky","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R406","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1542\/peds.18.6.856","article-title":"Brain tumors in children; clinical analysis of 164 cases.","volume":"18","author":"Davis","year":"1956","journal-title":"Pediatrics"},{"key":"2020071611563648000_R407","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1227\/00006123-199502000-00004","article-title":"Pediatric pituitary adenomas.","volume":"36","author":"Mindermann","year":"1995","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R408","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000413656","article-title":"Problems in the treatment of children with brain tumors.","volume":"30","author":"Sano","year":"1987","journal-title":"Prog Exp Tumor Res"},{"key":"2020071611563648000_R409","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/00006123-199804000-00037","article-title":"Clinically nonsecreting pituitary adenomas in childhood and adolescence.","volume":"42","author":"Abe","year":"1998","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1227\/00006123-199907000-00001","article-title":"Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery.","volume":"45","author":"Abe","year":"1999","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R411","first-page":"315","article-title":"Comprehensive management of pituitary disorders.","author":"Boop","year":"1999"},{"key":"2020071611563648000_R412","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000413694","article-title":"Pituitary adenomas in childhood and adolescence.","volume":"30","author":"Laws","year":"1987","journal-title":"Prog Exp Tumor Res"},{"key":"2020071611563648000_R413","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000413695","article-title":"Special problems with neurosurgical treatments of hormone-secreting pituitary adenomas in children.","volume":"30","author":"Ludecke","year":"1987","journal-title":"Prog Exp Tumor Res"},{"key":"2020071611563648000_R414","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1227\/00006123-199110000-00004","article-title":"Pediatric pituitary tumors.","volume":"29","author":"Haddad","year":"1991","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R415","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1210\/jcem.84.12.6215","article-title":"Pituitary tumors in children and adolescents.","volume":"84","author":"Lafferty","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R416","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archpedi.1993.02160340043011","article-title":"Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.","volume":"147","author":"Tyson","year":"1993","journal-title":"Am J Dis Child"},{"key":"2020071611563648000_R417","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 5","key":"2020071611563648000_R418","first-page":"1227","article-title":"Prolactinomas in children and adolescents\u2014consequences in adult life.","volume":"14","author":"Duntas","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071611563648000_R419","first-page":"87","article-title":"Combined bromocriptine and growth hormone (GH) treatment in GH-deficient children with macroprolactinoma in situ.","volume":"75","author":"Oberfield","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R420","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2265.2003.01748.x","article-title":"Clinical presentation and outcome of pituitary adenomas in teenagers.","volume":"58","author":"Cannavo","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R421","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1507\/endocrj.49.635","volume":"49","author":"Oiwa","journal-title":"Endocr J"},{"key":"2020071611563648000_R422","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1530\/acta.0.1250392","article-title":"Prolactinoma and body weight: a retrospective study.","volume":"125","author":"Creemers","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R423","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2265.1999.00700.x","article-title":"Hyperprolactinaemia as a reversible cause of weight gain in male patients?","volume":"50","author":"Delgrange","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R424","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R425","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R426","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.","volume":"75","author":"Biller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R427","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women.","volume":"303","author":"Klibanski","year":"1980","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R428","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.","volume":"64","author":"Schlechte","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R429","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R430","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/09513599609023603","article-title":"A study of the clinical differences between women and men with hyperprolactinemia.","volume":"10","author":"Ramot","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"2020071611563648000_R431","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF03349742","article-title":"Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).","volume":"18","author":"Berezin","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R432","first-page":"205","article-title":"Follow-up of sixty nine patients after pituitary tumor removal for hyperprolactinemia.","volume":"584","author":"Camanni","year":"1982","journal-title":"Excerpta Med Int Congr Ser"},{"key":"2020071611563648000_R433","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0002-9378(80)90392-0","article-title":"Results of surgery in 114 patients with prolactin-secreting pituitary adenomas.","volume":"137","author":"Domingue","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"2020071611563648000_R434","first-page":"2943","article-title":"Prolactioma in man. Pre- and post-operative study in 80 cases.","volume":"60","author":"Dupuy","year":"1984","journal-title":"Sem Hop Paris"},{"key":"2020071611563648000_R435","first-page":"91","author":"Goodman","year":"1980"},{"key":"2020071611563648000_R436","first-page":"241","article-title":"Prolactin secreting adenoma in 22 men.","volume":"13","author":"Grisoli","year":"1980","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R437","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.0954-6820.1985.tb01642.x","article-title":"Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment.","volume":"217","author":"Hulting","year":"1985","journal-title":"Acta Med Scand"},{"key":"2020071611563648000_R438","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2265.1981.tb00618.x","article-title":"Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy.","volume":"14","author":"Pelkonen","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R439","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(82)90975-8","article-title":"Hyperprolactinaemia in men\u2014response to bromocriptine therapy.","volume":"1","author":"Prescott","year":"1982","journal-title":"Lancet"},{"key":"2020071611563648000_R440","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(82)91094-7","article-title":"Hyperprolactinaemia in males with and without pituitary macroadenomas.","volume":"2","author":"Spark","year":"1982","journal-title":"Lancet"},{"key":"2020071611563648000_R441","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1445-5994.1997.tb02196.x","article-title":"Hyperprolactinaemia in males: a heterogeneous disorder.","volume":"27","author":"Walsh","year":"1997","journal-title":"Aust N Z J Med"},{"key":"2020071611563648000_R442","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4065\/73.11.1046","article-title":"Prolactinomas in male and female patients: a comparative clinicopathologic study.","volume":"73","author":"Calle-Rodrigue","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"2020071611563648000_R443","first-page":"1782","article-title":"[Hyperprolactinemia in the male: clinical aspects and therapy].","volume":"111","author":"Eversmann","year":"1981","journal-title":"Schweiz Med Wochenschr"},{"key":"2020071611563648000_R444","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men.","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2020071611563648000_R445","first-page":"37","article-title":"[Prolactinoma in the male","volume":"27","author":"Somma","year":"1981","journal-title":"Preoperative evaluation of 40 patients]. Neurochirurgie"},{"key":"2020071611563648000_R446","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2003-030852","article-title":"Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence.","volume":"89","author":"De Rosa","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R447","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-64-2-391","article-title":"Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen.","volume":"64","author":"Prior","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R448","first-page":"2642","article-title":"Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.","volume":"81","author":"Burgess","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R449","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00006123-199608000-00008","article-title":"Results of treatment of pituitary disease in multiple endocrine neoplasia, type I.","volume":"39","author":"O\u2019Brien","year":"1996","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R450","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.","volume":"87","author":"Verges","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R451","first-page":"227","article-title":"Giant invasive prolactinoma: a case report and review of nine further cases.","volume":"74","author":"Davis","year":"1990","journal-title":"Q J Med"},{"key":"2020071611563648000_R452","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/S0317167100030055","article-title":"Surgical management of giant pituitary adenomas.","volume":"17","author":"Mohr","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"2020071611563648000_R453","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01815445","article-title":"Giant pituitary adenomas.","volume":"8","author":"Pia","year":"1985","journal-title":"Neurosurg Rev"},{"key":"2020071611563648000_R454","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.42.11.973","article-title":"Surgical treatment of giant pituitary adenomas.","volume":"42","author":"Symon","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020071611563648000_R455","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2265.2003.01770.x","article-title":"Giant prolactinomas in men: efficacy of cabergoline treatment.","volume":"58","author":"Corsello","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R456","first-page":"129","article-title":"Treatment of extensively invasive (giant) prolactinomas with bromocriptine.","volume":"105","author":"Grebe","year":"1992","journal-title":"N Z Med J"},{"key":"2020071611563648000_R457","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-119-2-199307150-00029","article-title":"Immunoradiometric assays may miss high prolactin levels.","volume":"119","author":"Comtois","year":"1993","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R458","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/clinchem\/38.3.437","article-title":"Two automated prolactin immunoassays evaluated with demonstration of a high-dose \u201chook effect\u201d in one.","volume":"38","author":"Haller","year":"1992","journal-title":"Clin Chem"},{"key":"2020071611563648000_R459","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2265.1996.663486.x","article-title":"High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.","volume":"44","author":"St-Jean","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R460","first-page":"656","article-title":"The hook effect in prolactin immunoassays.","volume":"25","author":"Al Sifri","year":"2004","journal-title":"Saudi Med J"},{"key":"2020071611563648000_R461","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00006123-199804000-00126","article-title":"Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the \u201chigh-dose hook effect\u201d: case report.","volume":"42","author":"Barkan","year":"1998","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R462","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4158\/EP.8.4.296","article-title":"\u201cHook effect\u201d in prolactinomas: case report and review of literature.","volume":"8","author":"Frieze","year":"2002","journal-title":"Endocr Pract"},{"key":"2020071611563648000_R463","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1025334001748","article-title":"Falsely low serum prolactin in two cases of invasive macroprolactinoma.","volume":"5","author":"Schofl","year":"2002","journal-title":"Pituitary"},{"key":"2020071611563648000_R464","first-page":"2","author":"Molitch","year":"1996"},{"key":"2020071611563648000_R465","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3171\/jns.1983.59.3.0395","article-title":"Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results.","volume":"59","author":"Ciric","year":"1983","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R466","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01456107","article-title":"Results of surgical management of 319 pituitary adenomas.","volume":"85","author":"Guidetti","year":"1987","journal-title":"Acta Neurochir (Wien)"},{"key":"2020071611563648000_R467","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.surneu.2003.08.036","article-title":"Giant pituitary tumors: a study based on surgical treatment of 118 cases.","volume":"61","author":"Goel","year":"2004","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R468","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/02688690220131723","article-title":"Giant pituitary adenomas: clinical characteristics and surgical results.","volume":"16","author":"Garibi","year":"2002","journal-title":"Br J Neurosurg"},{"key":"2020071611563648000_R469","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jocn.2002.11.002","article-title":"Treatments of multi-invasive giant prolactinoma.","volume":"11","author":"Yang","year":"2004","journal-title":"J Clin Neurosci"},{"key":"2020071611563648000_R470","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","article-title":"Pituitary carcinoma: a clinicopathologic study of 15 cases.","volume":"79","author":"Pernicone","year":"1997","journal-title":"Cancer"},{"key":"2020071611563648000_R471","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/1097-0142(19911001)68:7<1605::AID-CNCR2820680723>3.0.CO;2-D","article-title":"Prolactin-producing pituitary carcinoma with pulmonary metastases.","volume":"68","author":"Atienza","year":"1991","journal-title":"Cancer"},{"key":"2020071611563648000_R472","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/02688699746177","article-title":"Prolactin-secreting carcinoma of the pituitary: clinicopathological and immunohistochemical study of a case with intracranial and intraspinal dissemination.","volume":"11","author":"Bayindir","year":"1997","journal-title":"Br J Neurosurg"},{"key":"2020071611563648000_R473","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1530\/acta.0.1270476","article-title":"Malignant prolactinoma.","volume":"127","author":"Berezin","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R474","first-page":"89","article-title":"ras Mutations in human prolactinomas and pituitary carcinomas.","volume":"78","author":"Cai","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2265.1983.tb03210.x","article-title":"An intracranial metastasis from a PRL secreting pituitary tumour.","volume":"18","author":"Cohen","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R476","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/BF03351046","article-title":"Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.","volume":"24","author":"Fujikawa","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R477","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2265.1985.tb01060.x","article-title":"Multiple intracranial metastases from a prolactin secreting pituitary tumour.","volume":"22","author":"Gasser","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R478","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/1097-0142(19951115)76:10<1814::AID-CNCR2820761021>3.0.CO;2-T","article-title":"Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review.","volume":"76","author":"Gollard","year":"1995","journal-title":"Cancer"},{"key":"2020071611563648000_R479","first-page":"230","article-title":"Prolactin cell carcinoma of the pituitary.","volume":"76","author":"Kasantikul","year":"1993","journal-title":"J Med Assoc Thai"},{"key":"2020071611563648000_R480","first-page":"116","article-title":"Malignant prolactinoma with multiple bone and pulmonary metastases. Case report.","volume":"101","author":"Lamas","year":"2004","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R481","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF01731658","article-title":"Hormone-active intradural spinal metastasis of a prolactinoma\u2014a case report.","volume":"63","author":"Landgraf","year":"1985","journal-title":"Klin Wochenschr"},{"key":"2020071611563648000_R482","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0009-9260(05)81807-0","article-title":"Case report: multiple intra-cranial metastases from a prolactin-secreting pituitary tumour.","volume":"49","author":"Long","year":"1994","journal-title":"Clin Radiol"},{"key":"2020071611563648000_R483","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3171\/jns.1981.55.4.0615","article-title":"Cerebellar metastasis from a prolactinoma during treatment with bromocriptine.","volume":"55","author":"Martin","year":"1981","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R484","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1227\/00006123-198802000-00017","article-title":"Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography.","volume":"22","author":"Muhr","year":"1988","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R485","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02688699550041584","article-title":"Intracranial metastases from pituitary adenoma.","volume":"9","author":"O\u2019Brien","year":"1995","journal-title":"Br J Neurosurg"},{"key":"2020071611563648000_R486","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/jnnp.55.12.1205","article-title":"Prolactin secreting pituitary carcinoma.","volume":"55","author":"Petterson","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020071611563648000_R487","first-page":"235","article-title":"Subarachnoid metastases from a prolactinoma.","volume":"28","author":"Plangger","year":"1985","journal-title":"Neurochirurgia (Stuttg)"},{"key":"2020071611563648000_R488","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0090-3019(97)00458-8","article-title":"Malignant prolactinoma: case report and review of the literature.","volume":"51","author":"Popadic","year":"1999","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R489","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1227\/00006123-199107000-00023","article-title":"Malignant prolactinomas.","volume":"29","author":"Popovic","year":"1991","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R490","first-page":"172","article-title":"Malignant growth of a recurrent macroprolactinoma after radiation therapy.","volume":"36","author":"Rainov","year":"1993","journal-title":"Neurochirurgia (Stuttg)"},{"key":"2020071611563648000_R491","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2214\/ajr.167.5.8911199","article-title":"Intrathecal metastatic pituitary prolactinoma.","volume":"167","author":"Rockwell","year":"1996","journal-title":"AJR Am J Roentgenol"},{"key":"2020071611563648000_R492","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s002920050114","article-title":"[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor].","volume":"16","author":"Saeger","year":"1995","journal-title":"Pathologe"},{"key":"2020071611563648000_R493","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/1097-0142(19850201)55:3<598::AID-CNCR2820550320>3.0.CO;2-S","article-title":"Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.","volume":"55","author":"Scheithauer","year":"1985","journal-title":"Cancer"},{"key":"2020071611563648000_R494","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0046-8177(84)80339-1","article-title":"Metastatic prolactin-secreting pituitary adenoma.","volume":"15","author":"U","year":"1984","journal-title":"Hum Pathol"},{"key":"2020071611563648000_R495","first-page":"37","article-title":"Malignant prolactinoma: is metastasis a must? Clinico-pathologic and immunohistochemical study of a case.","volume":"48","author":"Vaishya","year":"2004","journal-title":"J Neurosurg Sci"},{"key":"2020071611563648000_R496","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2265.1993.tb00523.x","article-title":"Malignant prolactinoma with extracranial metastases: a report of three cases.","volume":"38","author":"Walker","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R497","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jcp.55.2.148","article-title":"Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report.","volume":"55","author":"Sironi","year":"2002","journal-title":"J Clin Pathol"},{"key":"2020071611563648000_R498","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Clinical review: diagnosis and management of pituitary carcinomas.","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R499","first-page":"1066","article-title":"Pituitary carcinoma: a clinicopathological review.","volume":"56","author":"Scheithauer","year":"2005","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R500","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/foc.2004.16.4.8","article-title":"Pituitary carcinoma: a review of the literature","volume":"16","author":"Ragel","year":"2004","journal-title":"Neurosurg Focus"},{"key":"2020071611563648000_R501","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1009975009924","article-title":"Malignant pituitary tumours.","volume":"1","author":"Kaltsas","year":"1998","journal-title":"Pituitary"},{"key":"2020071611563648000_R502","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","article-title":"Temozolomide: a novel treatment for pituitary carcinoma.","volume":"7","author":"Lim","year":"2006","journal-title":"Lancet Oncol"},{"key":"2020071611563648000_R503","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","article-title":"Somatostatin analogs in acromegaly.","volume":"87","author":"Freda","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R504","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"key":"2020071611563648000_R505","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem-60-5-985","article-title":"Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.","volume":"60","author":"Ishibashi","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R506","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem-60-3-599","article-title":"Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture.","volume":"60","author":"Ishibashi","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R507","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1011796","article-title":"Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia.","volume":"19","author":"Bronstein","year":"1987","journal-title":"Horm Metab Res"},{"key":"2020071611563648000_R508","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1986.tb01683.x","article-title":"The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201\u2013995 in patients with prolactinomas and acromegaly.","volume":"25","author":"Lamberts","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R509","first-page":"1386","article-title":"Somatostatin receptor subtype gene expression in pituitary adenomas.","volume":"80","author":"Miller","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R510","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","article-title":"Expression of mRNA for all five human somatostatin receptors (hSSTR1\u20135) in pituitary tumors.","volume":"56","author":"Panetta","year":"1995","journal-title":"Life Sci"},{"key":"2020071611563648000_R511","first-page":"724","article-title":"Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.","volume":"79","author":"Greenman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R512","first-page":"398","article-title":"Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.","volume":"78","author":"Greenman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R513","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1210\/jcem.82.9.4252","article-title":"Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary and islet cell tumors.","volume":"82","author":"Hofland","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R514","first-page":"3268","article-title":"Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.","volume":"84","author":"Jaquet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R515","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2826.1996.tb00695.x","article-title":"Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.","volume":"8","author":"Murabe","year":"1996","journal-title":"J Neuroendocrinol"},{"key":"2020071611563648000_R516","first-page":"2997","article-title":"Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.","volume":"83","author":"Nielsen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R517","first-page":"235","author":"Hofland","year":"2004"},{"key":"2020071611563648000_R518","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","article-title":"The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R519","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity.","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"2020071611563648000_R520","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor.","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"2020071611563648000_R521","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/eje.1.01950","article-title":"Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.","volume":"153","author":"Jaquet","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R522","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1210\/jc.2003-030302","article-title":"Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin\/dopaminergic chimeric ligand.","volume":"88","author":"Ren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R523","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1210\/jc.2002-020934","article-title":"Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.","volume":"87","author":"Saveanu","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R524","first-page":"233","article-title":"Estrogens and the genetic control of tumor growth.","volume":"396","author":"Gorski","year":"1997","journal-title":"Prog Clin Biol Res"},{"key":"2020071611563648000_R525","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1210\/jcem-66-2-444","article-title":"Estrogen-induced prolactinoma in a man.","volume":"66","author":"Gooren","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R526","first-page":"3177","article-title":"Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient.","volume":"81","author":"Serri","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R527","first-page":"1058","article-title":"Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas.","volume":"82","author":"Chaidarun","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R528","first-page":"3308","article-title":"Differential expression of estrogen receptor-\u03b2 (ER \u03b2) in human pituitary tumors: functional interactions with ER \u03b1 and a tumor-specific splice variant.","volume":"83","author":"Chaidarun","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R529","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0890-6238(98)00003-3","article-title":"The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.","volume":"12","author":"Buelke-Sam","year":"1998","journal-title":"Reprod Toxicol"},{"key":"2020071611563648000_R530","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000217826","article-title":"Effects of 17 \u03b2-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors.","volume":"14","author":"Caronti","year":"1993","journal-title":"Tumour Biol"},{"key":"2020071611563648000_R531","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1210\/endo-106-3-702","article-title":"Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine.","volume":"106","author":"Uijada","year":"1980","journal-title":"Endocrinology"},{"key":"2020071611563648000_R532","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0304-3940(00)01270-2","article-title":"Luteinizing hormone secretion elicited in a ligand-independent activation of progesterone receptor manner at pituitary level in the rat: differential effect of two selective estrogen receptor modulators.","volume":"289","author":"Gonzalez","year":"2000","journal-title":"Neurosci Lett"},{"key":"2020071611563648000_R533","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF03349368","article-title":"The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.","volume":"3","author":"Lamberts","year":"1980","journal-title":"J Endocrinol Invest"},{"key":"2020071611563648000_R534","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0277-5379(87)90143-X","article-title":"Differences in the mechanism of the inhibitory actions of catecholestrogens, tamoxifen and high concentrations of estrogens on prolactin release by cultured rat pituitary tumor cells.","volume":"23","author":"Lamberts","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2020071611563648000_R535","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000123324","article-title":"Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.","volume":"34","author":"Lamberts","year":"1982","journal-title":"Neuroendocrinology"},{"key":"2020071611563648000_R536","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/eje.0.1470461","article-title":"Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.","volume":"147","author":"Lasco","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R537","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02104-8","article-title":"Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats.","volume":"311","author":"Pinilla","year":"2001","journal-title":"Neurosci Lett"},{"key":"2020071611563648000_R538","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0303-7207(85)90131-5","article-title":"Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs.","volume":"39","author":"Simard","year":"1985","journal-title":"Mol Cell Endocrinol"},{"key":"2020071611563648000_R539","first-page":"17","volume-title":"Proc of the 9th International Pituitary Congress","author":"Popii","year":"2005"},{"key":"2020071611563648000_R540","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2005.04.008","article-title":"Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.","volume":"239","author":"Kansra","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"2020071611563648000_R541","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1517\/14656566.5.12.2549","article-title":"Fulvestrant: a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.","volume":"5","author":"Possinger","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"2020071611563648000_R542","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI0214264","article-title":"Functional role of estrogen in pituitary tumor pathogenesis.","volume":"109","author":"Heaney","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611563648000_R543","first-page":"4677","article-title":"Estrogen: consequences and implications of human mutations in synthesis and action.","volume":"84","author":"Grumbach","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R544","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2005.04.009","article-title":"Long-term effects of aromatase inhibitors on bone.","volume":"95","author":"Eastell","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2020071611563648000_R545","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists.","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocr Rev"},{"key":"2020071611563648000_R546","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1043-2760(02)00603-3","article-title":"Prolactin as an autocrine\/paracrine growth factor in human cancer.","volume":"13","author":"Ben-Jonathan","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"2020071611563648000_R547","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma.","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr Rev"},{"key":"2020071611563648000_R548","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2265.1995.tb02667.x","article-title":"Prolactin receptors in human pituitary adenomas.","volume":"42","author":"Ciccarelli","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R549","first-page":"963","article-title":"Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues.","volume":"82","author":"Jin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R550","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI0215912","article-title":"Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.","volume":"110","author":"Schuff","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611563648000_R551","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1210\/endo.139.9.6209","article-title":"Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene.","volume":"139","author":"Steger","year":"1998","journal-title":"Endocrinology"},{"key":"2020071611563648000_R552","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1566523044578086","article-title":"Potential of gene therapy for the treatment of pituitary tumors.","volume":"4","author":"Goya","year":"2004","journal-title":"Curr Gene Ther"},{"key":"2020071611563648000_R553","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1677\/joe.1.06023","article-title":"Gene therapy of pituitary diseases.","volume":"185","author":"Lee","year":"2005","journal-title":"J Endocrinol"},{"key":"2020071611563648000_R554","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0091-3022(02)00106-1","article-title":"Gene therapy for pituitary tumors: from preclinical models to clinical implementation.","volume":"24","author":"Castro","year":"2003","journal-title":"Front Neuroendocrinol"},{"key":"2020071611563648000_R555","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2265.2001.01400.x","article-title":"Is pituitary gene therapy realistic?","volume":"55","author":"Davis","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R556","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199605023341809","article-title":"Adenoviruses as gene-delivery vehicles.","volume":"334","author":"Wilson","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071611563648000_R557","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/10430340252809829","article-title":"Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy.","volume":"13","author":"Lee","year":"2002","journal-title":"Hum Gene Ther"},{"key":"2020071611563648000_R558","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1210\/endo.142.6.8183","article-title":"Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo.","volume":"142","author":"Smith-Arica","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611563648000_R559","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1006\/mthe.2001.0499","article-title":"Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.","volume":"4","author":"Williams","year":"2001","journal-title":"Mol Ther"},{"key":"2020071611563648000_R560","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1566523033347426","article-title":"Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene\/ganciclovir system: fifteen years of application.","volume":"3","author":"Fillat","year":"2003","journal-title":"Curr Gene Ther"},{"key":"2020071611563648000_R561","first-page":"279","article-title":"Drug sensitivity (\u201csuicide\u201d) genes for selective cancer chemotherapy.","volume":"1","author":"Moolten","year":"1994","journal-title":"Cancer Gene Ther"},{"key":"2020071611563648000_R562","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1210\/endo.142.2.7963","article-title":"Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: an in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy.","volume":"142","author":"Davis","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611563648000_R563","first-page":"1296","article-title":"Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses estrogen-induced pituitary prolactinomas.","volume":"85","author":"Windeatt","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R564","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1210\/endo.141.9.7639","article-title":"Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen\/sulpiride-induced hyperplastic anterior pituitaries.","volume":"141","author":"Southgate","year":"2000","journal-title":"Endocrinology"},{"key":"2020071611563648000_R565","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1210\/endo.142.9.8372","article-title":"Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice.","volume":"142","author":"Lee","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611563648000_R566","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1210\/endo.136.3.7867574","article-title":"Nerve growth factor promotes the differentiation of pituitary mammotroph cells in vitro.","volume":"136","author":"Missale","year":"1995","journal-title":"Endocrinology"},{"key":"2020071611563648000_R567","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group.","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"key":"2020071611563648000_R568","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.57.7.1313","article-title":"Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.","volume":"57","author":"Schifitto","year":"2001","journal-title":"Neurology"},{"key":"2020071611563648000_R569","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0090-9556(24)15106-9","article-title":"Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys.","volume":"28","author":"Nguyen","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"2020071611563648000_R570","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat Med"},{"key":"2020071611563648000_R571","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1568008054863817","article-title":"Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs.","volume":"5","author":"Paez-Pereda","year":"2005","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"2020071611563648000_R572","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrc1320","article-title":"Molecular targets in pituitary tumours.","volume":"4","author":"Heaney","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2020071611563648000_R573","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.seminoncol.2004.01.009","article-title":"Molecular therapeutics: promise and challenges.","volume":"31","author":"Kohn","year":"2004","journal-title":"Semin Oncol"},{"key":"2020071611563648000_R574","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrc926","article-title":"The pathogenesis of pituitary tumours.","volume":"2","author":"Asa","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2020071611563648000_R575","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1210\/jc.2003-031633","article-title":"Pituitary tumor pathogenesis\u2014the hunt for novel candidate genes continues.","volume":"88","author":"Ezzat","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R576","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.","volume":"183","author":"Fagin","year":"2004","journal-title":"J Endocrinol"},{"key":"2020071611563648000_R577","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/428379b","article-title":"Medicine: profile of a tumour.","volume":"428","author":"Kallioniemi","year":"2004","journal-title":"Nature"},{"key":"2020071611563648000_R578","first-page":"141","article-title":"Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: prolactin levels and tumor size as predicting factors.","volume":"14","author":"Aubourg","year":"1980","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R579","first-page":"483","author":"Nicola","year":"1980"},{"key":"2020071611563648000_R580","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1530\/acta.0.0940450","article-title":"The clinical and biochemical features in 26 patients with prolactinoma before and after transsphenoidal microresection.","volume":"94","author":"Samaan","year":"1980","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R581","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-94-3-302","article-title":"Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal.","volume":"94","author":"Tucker","year":"1981","journal-title":"Ann Intern Med"},{"key":"2020071611563648000_R582","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3171\/jns.1982.56.1.0033","article-title":"Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas.","volume":"56","author":"Faria Jr","year":"1982","journal-title":"J Neurosurg"},{"key":"2020071611563648000_R583","first-page":"189","article-title":"Follow-up review of microprolactinomas operated in 48 female patients.","volume":"584","author":"Giovanelli","year":"1982","journal-title":"Excerpta Med Int Congr Ser"},{"key":"2020071611563648000_R584","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00007611-198208000-00015","article-title":"Transsphenoidal surgery for prolactin-secreting pituitary tumors: a study of 28 cases and review of the literature.","volume":"75","author":"Smallridge","year":"1982","journal-title":"South Med J"},{"key":"2020071611563648000_R585","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0015-0282(16)45977-7","article-title":"Prolactin-secreting pituitary adenomas: neurosurgical management of 37 patients.","volume":"37","author":"Woosley","year":"1982","journal-title":"Fertil Steril"},{"key":"2020071611563648000_R586","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1227\/00006123-198312000-00002","article-title":"Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas.","volume":"13","author":"Nelson","year":"1983","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R587","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.1984.03350070039020","article-title":"Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma.","volume":"252","author":"Rodman","year":"1984","journal-title":"JAMA"},{"key":"2020071611563648000_R588","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1055\/s-2008-1069047","article-title":"[Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].","volume":"110","author":"Brabant","year":"1985","journal-title":"Dtsch Med Wochenschr"},{"key":"2020071611563648000_R589","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0026-0495(86)90052-1","article-title":"Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies.","volume":"35","author":"Arafah","year":"1986","journal-title":"Metabolism"},{"key":"2020071611563648000_R590","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1097-0142(19860615)57:12<2422::AID-CNCR2820571229>3.0.CO;2-B","article-title":"Late recurrence of surgically removed prolactinomas.","volume":"57","author":"Parl","year":"1986","journal-title":"Cancer"},{"issue":"Suppl 1","key":"2020071611563648000_R591","first-page":"34","article-title":"The use of surgery for the treatment of prolactinomas","volume":"129","author":"Verlaat","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071611563648000_R592","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/bmj.309.6966.1409","article-title":"Ten-year follow-up of microprolactinoma treated by transsphenoidal surgery.","volume":"309","author":"Thomson","year":"1994","journal-title":"BMJ"},{"key":"2020071611563648000_R593","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2265.1996.738559.x","article-title":"The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.","volume":"44","author":"Soule","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R594","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1210\/jcem.82.6.3880","article-title":"A decade of the Massachusetts General Hospital Neuroendocrine Clinical Center.","volume":"82","author":"Biller","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R595","first-page":"65","article-title":"A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma.","volume":"45","author":"Acquati","year":"2001","journal-title":"J Neurosurg Sci"},{"key":"2020071611563648000_R596","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0090-3019(02)00714-0","article-title":"Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence.","volume":"57","author":"Abe","year":"2002","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R597","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10072-004-0351-z","article-title":"Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.","volume":"25","author":"Esposito","year":"2004","journal-title":"Neurol Sci"},{"key":"2020071611563648000_R598","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1227\/01.NEU.0000159647.64275.9D","article-title":"Results of transsphenoidal surgery in a large series of patients with pituitary adenoma.","volume":"56","author":"Mortini","year":"2005","journal-title":"Neurosurgery"},{"key":"2020071611563648000_R599","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","article-title":"Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.","volume":"69","author":"Ciccarelli","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R600","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/jcem-68-6-1201","article-title":"Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.","volume":"68","author":"Ferrari","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R601","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1507\/endocrj.45.529","article-title":"Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.","volume":"45","author":"Saeki","year":"1998","journal-title":"Endocr J"},{"key":"2020071611563648000_R602","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0090-3019(01)00697-8","article-title":"Giant prolactinomas presenting as skull base tumors.","volume":"57","author":"Minniti","year":"2002","journal-title":"Surg Neurol"},{"key":"2020071611563648000_R603","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and cyclin E expression in normal and adenomatous pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"2020071611563648000_R604","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jcem.74.4.1312542","article-title":"Ras mutations in human pituitary tumors.","volume":"74","author":"Karga","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R605","first-page":"842","article-title":"H-ras mutations in human pituitary carcinoma metastases.","volume":"78","author":"Pei","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R606","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/me.2004-0403","article-title":"Early multipotential pituitary focal hyperplasia in the \u03b1-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice.","volume":"19","author":"Abbud","year":"2005","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R607","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/jcem.84.2.5432","article-title":"Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.","volume":"84","author":"Zhang","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611563648000_R608","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/me.2004-0182","article-title":"Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule\/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.","volume":"18","author":"Ezzat","year":"2004","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R609","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI14036","article-title":"Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.","volume":"109","author":"Ezzat","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611563648000_R610","doi-asserted-by":"crossref","first-page":"19597","DOI":"10.1074\/jbc.M212432200","article-title":"Pituitary tumor AP-2\u03b1 recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4.","volume":"278","author":"Yu","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071611563648000_R611","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1038\/sj.onc.1205428","article-title":"Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas.","volume":"21","author":"Fedele","year":"2002","journal-title":"Oncogene"},{"key":"2020071611563648000_R612","first-page":"2398","article-title":"The high mobility group A2 gene is amplified and overexpressed in human prolactinomas.","volume":"62","author":"Finelli","year":"2002","journal-title":"Cancer Res"},{"key":"2020071611563648000_R613","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1073\/pnas.0237312100","article-title":"Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad\/estrogen receptor crosstalk.","volume":"100","author":"Paez-Pereda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611563648000_R614","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1210\/mend.12.9.0170","article-title":"A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression.","volume":"12","author":"Chaidarun","year":"1998","journal-title":"Mol Endocrinol"},{"key":"2020071611563648000_R615","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1073\/pnas.98.3.1118","article-title":"A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.","volume":"98","author":"Crabtree","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611563648000_R616","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/359295a0","article-title":"Effects of an Rb mutation in the mouse.","volume":"359","author":"Jacks","year":"1992","journal-title":"Nature"},{"key":"2020071611563648000_R617","first-page":"1211","article-title":"Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.","volume":"60","author":"Simpson","year":"2000","journal-title":"Cancer Res"},{"key":"2020071611563648000_R618","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2265.1999.00774.x","article-title":"p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours.","volume":"51","author":"Jaffrain-Rea","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071611563648000_R619","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35092592","article-title":"Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.","volume":"413","author":"Sharpless","year":"2001","journal-title":"Nature"},{"key":"2020071611563648000_R620","first-page":"2493","article-title":"Frequent loss of the P16INK4a gene product in human pituitary tumors.","volume":"56","author":"Woloschak","year":"1996","journal-title":"Cancer Res"},{"key":"2020071611563648000_R621","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/endo.140.11.7118","article-title":"Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.","volume":"140","author":"Asa","year":"1999","journal-title":"Endocrinology"},{"key":"2020071611563648000_R622","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0896-6273(00)80351-7","article-title":"Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice.","volume":"19","author":"Kelly","year":"1997","journal-title":"Neuron"},{"key":"2020071611563648000_R623","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/endo.140.11.7120","article-title":"Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia.","volume":"140","author":"Cai","year":"1999","journal-title":"Endocrinology"},{"key":"2020071611563648000_R624","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1073\/pnas.89.7.2764","article-title":"Pituitary hyperplasia induced by ectopic expression of nerve growth factor.","volume":"89","author":"Borrelli","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611563648000_R625","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1210\/endo.136.10.7664668","article-title":"Targeting of transforming growth factor-\u03b1 expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.","volume":"136","author":"McAndrew","year":"1995","journal-title":"Endocrinology"},{"key":"2020071611563648000_R626","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/RRS-200029981","article-title":"Dopamine receptor signaling.","volume":"24","author":"Neve","year":"2004","journal-title":"J Recept Signal Transduct Res"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/27\/5\/485\/8862211\/edrv0485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/27\/5\/485\/8862211\/edrv0485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:20:28Z","timestamp":1736486428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/27\/5\/485\/2355195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,26]]},"references-count":626,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2005-9998","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,26]]}}}